However, it is worth noting that, despite researchers validating the role of LGALS1 in AML chemotherapy resistance through various experimental methods, further clinical research is still needed to evaluate the feasibility and effectiveness of LGALS1 as a potential treatment target. This evidence concerns the gene LGALS1 and acute myeloid leukemia.